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The nuclear hormone receptor retinoic acid-related orphan re-
ceptor gamma t (RORγt) is a transcription factor (TF) specific to
TH17 cells that produce interleukin (IL)-17 and have been impli-
cated in a wide range of autoimmunity. Here, we developed
a novel therapeutic strategy to modulate the functions of RORγt
using cell-transducible form of transcription modulation domain of
RORγt (tRORγt-TMD), which can be delivered effectively into the nu-
cleus of cells and into the central nerve system (CNS). tRORγt-TMD
specifically inhibited TH17-related cytokines induced by RORγt,
thereby suppressing the differentiation of naïve T cells into TH17,
but not into TH1, TH2, or Treg cells. tRORγt-TMD injected into experi-
mental autoimmune encephalomyelitis (EAE) animal model can be
delivered effectively in the splenic CD4+ T cells and spinal cord-infil-
trating CD4+ T cells, and suppress the functions of TH17 cells. The
clinical severity and incidence of EAE were ameliorated by tRORγt-
TMD in preventive and therapeutic manner, and significant reduction
of both infiltrating CD4+ IL-17+ T cells and inflammatory cells into the
CNS was observed. As a result, the number of spinal cord demyelin-
ation was also reduced after tRORγt-TMD treatment. With the same
proof of concept, tTbet-TMD specifically blocking TH1 differentiation
improved the clinical incidence of rheumatoid arthritis (RA). There-
fore, tRORγt-TMD and tTbet-TMD can be novel therapeutic reagents
with the natural specificity for the treatment of inflammatory dis-
eases associated with TH17 or TH1. This strategy can be applied to
treat various diseases where a specific transcription factor has a key
role in pathogenesis.
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Naïve CD4+ T cells initiate a process of differentiation intoeffector CD4+ T cells upon stimulation with specific anti-
gens. Infectious diseases were found to elicit preferentially a TH1
response, whereas parasitic infections provoke an expansion of
TH2. TH1 differentiation requires a specific transcription factor
Tbet and expresses IFN-γ, whereas TH2 needs GATA-3 and
secretes IL-4, IL-5, and IL-13 (1). Regulatory T-cell is essential
for the maintenance of peripheral tolerance and to control im-
mune response. Foxp3 is a key transcription factor and expresses
IL-10 to suppress or modulate the immune balance (2).
TH17 cells, a subset of T helper cells that secrete IL-17, pro-
vide host defense against bacterial and fungal infections. More
importantly, TH17 cells are involved in the development of var-
ious autoimmune and inflammatory diseases when they remain
active after clearance of the pathogens or the immunological
balance among T-cell subsets is disrupted (3, 4). The nuclear
hormone receptor retinoic acid-related orphan receptor gamma t
(RORγt) has been identified as the TH17-specific transcription
factor (5). IL-6 synergizes with transforming growth factor
(TGF)-β to promote the expression of RORγt in favor of TH17
differentiation, and continuous RORγt expression is required to
maintain the functions of TH17 cells in vivo (6, 7). In addition,
IL-23 is important for enhancing the survival, proliferation, and
pathological function of TH17 cells via induction of RORγt ex-
pression, and IL-21 is another cytokine that promotes the dif-
ferentiation of TH17 cells in an autocrine manner and inhibits
the induction of Foxp3 in Treg cells (8, 9).
TH1 cells cause the joint damage in rheumatoid arthritis (RA),
a chronic autoimmune disease characterized by inflammation in
the synovium leading to cartilage destruction, bone erosion, and
joint deformities, mainly through IFN-γ–driven inflammatory
mechanisms. However, mouse studies have demonstrated that the
development of autoimmune disease does not require IFN-γ,
suggesting that inhibition of expression or activity of Tbet can be
better treatment strategies for autoimmunity associated with TH1
cells (10).
Targeting RORγt in TH17 cells or Tbet in TH1 cells could be
therapeutically beneficial in the treatment of inflammatory au-
toimmune diseases. However, because transcription factors are
known to be one of the protein classes that are difficult to target,
a therapeutic agent aimed for specifically modulating the func-
tions of RORγt or Tbet has yet to be discovered (11). A systematic
understanding of the genomic targets of RORγt and the tran-
scriptional network that controls differentiation of TH17 cells is
beginning to emerge, and such knowledge will provides a unique
opportunity to elucidate the functions of TH17 cells. Indeed,
several small molecules such as digoxin (12), SR1001 (13), and
TMP778/TMP920/GSK805 (14) that can inhibit the function of
RORγt have been identified. Although these small molecules are
effective in inhibition of TH17-mediated autoimmunity in vitro
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and in vivo, their functional specificity and cellular toxicity need to
be thoroughly examined.
In this study, we demonstrated that tRORγt-TMD or tTbet-
TMD, which can delivered into the nucleus in vitro and in vivo,
and directly targets the endogenous RORγt or Tbet in interactomic
inhibitory manner, effectively suppresses differentiation of naïve T
cells into TH17 or TH1 cells, respectively, and their functions via
inhibition of RORγt- or Tbet-mediated gene expression without
affecting the differentiation of other T-cell subsets. tRORγt-TMD
or tTbet-TMD markedly alleviated autoimmunity associated with
TH17 or TH1 cells in preventive and therapeutic way. Therefore,
intranucleusly transducible form of transcription factor (TF)-TMD
(tTF-TMD) may be a fundamental and therapeutic strategy to
modulate the functions of transcription factor specifically associated
with various diseases, which can become a novel protein drug
candidate for the treatment of these diseases.
Results
tRORγt-TMD Can Be Delivered Into the Nucleus of the Cells
Effectively. The N terminus of RORγt has a transcription mod-
ulation domain (TMD) comprising DNA-binding amino acid
residues and isotype-specific sequences that may play key roles in
the functional specificity of RORγt (15). Thus, we designed a novel
therapeutics, tRORγt-TMD, to deliver RORγt-TMD efficiently
into the nucleus of the cells in vitro and in vivo, and thereby, the
delivered tRORγt-TMD competitively interferes with the tran-
scriptional activity of endogenous RORγt at the promoter of
RORγt-target genes. tRORγt-TMD was generated by fusing Hph-
1-PTD (protein transduction domain) with the TMD of RORγt
(16, 17). Nontransducible RORγt-TMD (RORγt-TMD), tRORγt-
TMD without DNA-binding capacity [tRORγt-TMD (RR-AG)],
and transducible RORγt-LBD (ligand-bindng domain, tRORγt-
LBD) were generated for experimental controls (Fig. 1 A and B
and Fig. S1A). Neither tRORγt-TMD nor the control proteins
resulted in cytotoxicity in mouse CD4+ T cells (Fig. S1B). The level
of endotoxin or bacterial DNA in each of the purified proteins was
not within the range of functional influence. As shown in Fig. 1,
tRORγt-TMD was transduced into mouse primary CD4+ T cells
effectively in a dose- and time-dependent manner (Fig. 1 C and D).
The delivered tRORγt-TMD remained inside the cells up to 48 h
after transduction. Following delivery of tRORγt-TMD to HeLa
cells, the majority of tRORγt-TMD was detected in the nucleus as
early as 1 h after transduction, which was analyzed by confocal
microscopy (Fig. 1E).
RORγt-Mediated Transcription Is Specifically Inhibited by tRORγt-
TMD. To examine the inhibitory effect of tRORγt-TMD on the
induced expression of IL-17, which is the prominent cytokine
induced by RORγt, HEK293 cells were cotransfected with
plasmids expressing wild-type RORγt and luciferase driven by the
IL-17A promoter (18). The transfected cells were then incubated
with tRORγt-TMD, and the luciferase activity was measured. The
tRORγt-TMD significantly reduced the RORγt-mediated lucif-
erase activity in a dose-dependent manner, whereas neither the
nontransducible RORγt-TMD nor the tRORγt-LBD affected this
activity. Interestingly, tRORγt-TMD (RR-AG), which cannot
bind to the IL-17A promoter, failed to attenuate the luciferase
activity (Fig. 1F). To demonstrate the functional specificity of
tRORγt-TMD, a similar experiment was performed by using two
plasmids expressing wild-type RORα1 instead of RORγt and lu-
ciferase driven by the apolipoprotein A5 (APOA5) promoter (19).
Inhibition of RORα1-mediated luciferase activity was not ob-
served by transduction of tRORγt-TMD (Fig. 1G). Therefore,
tRORγt-TMD can specifically inhibit the transcriptional activity of
endogenous RORγt on its target genes.
tRORγt-TMD Specifically Inhibits IL-17 Cytokine Production in T-Cell
Activation. To investigate whether tRORγt-TMD affects T-cell
activation or TcR-induced cytokine secretion from various
T-cell subsets, total splenocytes from C57BL/6 mice were in-
cubated with tRORγt-TMD for 1 h. The cells were washed and
stimulated with plate-bound anti-CD3 antibody and soluble anti-
CD28 antibody, and then the level of CD69 or FasL induction
on the surface and the secretion of cytokines specific to different
T-cell subsets were analyzed. Incubation with tRORγt-TMD did
Fig. 1. Generation of tRORγt-TMD, a transducible form of interactomic inhibitor of RORγt. (A) Structure of tRORγt-TMD and its derivatives: nontransducible
RORγt-TMD, tRORγt-TMD, a mutant form of tRORγt-TMD without DNA-binding capacity [tRORγt-TMD (RR-AG)], and tRORγt-LBD. (B) Intranuclear trans-
duction efficiency of RORγt-TMD, tRORγt-TMD, tRORγt-TMD (RR-AG), or tRORγt-LBD was examined by Western blot using with anti-FLAG antibody in mouse
primary CD4+ T cells after 1-h transduction. (C and D) Dose-dependent (1 h) (C) and time-dependent (D) intranuclear transduction kinetics of tRORγt-TMD was
analyzed with nuclear fraction of the cells by Western blot using with anti-FLAG antibody in mouse primary CD4+ T cells. (E) Intranuclear localization of
tRORγt-TMD after transduction analyzed by confocal microscopy. (F and G) Functional specificity of tRORγt-TMD was examined in HEK293 cells cotransfected
with the vectors expressing wild-type RORγt and luciferase driven by Il17-promoter (F) or with those expressing wild-type RORα1 and luciferase driven by
apolipoprotein A5-promoter (G). After 24 h, luciferase activity was analyzed and the value was normalized by Renilla acrivity. Data are representative of at
least five (B–D) and three (E–G) independent experiments. Error bars denote SEM. ***P < 0.001.
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not inhibit the production of IL-2 or the induction of CD69
and FasL on the surface upon T-cell activation (Fig. 2 A–C). In
addition, tRORγt-TMD substantially and specifically inhibited
IL-17A secretion but did not influence the level of IFN-γ and
IL-4 secretion from total splenocytes (Fig. 2 D–F). Thus,
tRORγt-TMD can specifically down-regulate RORγt-mediated
gene expression in TH17 cells by binding to its promoter with-
out affecting the common T-cell activation signals and tran-
scription of cytokines specific to TH1 or TH2 cells.
tRORγt-TMD Prevents TH17 Differentiation and Functions Without
Affecting Those of Other T-Cell Subsets. To determine whether
tRORγt-TMD can specifically inhibit TH17 differentiation, naïve
CD4+CD25−CD62Lhigh T cells were purified, incubated with
RORγt-TMD, tRORγt-TMD, or tRORγt-LBD, and then acti-
vated with plate-bound anti-CD3 and soluble anti-CD28 anti-
bodies in TH1-, TH2-, TH17-, or Treg-polarizing conditions. The
levels of IL-17A and IL-17F were significantly decreased
by tRORγt-TMD, but not by nontransducible RORγt-TMD
or tRORγt-LBD under TH17-polarizing condition in dose-
dependent manner (Fig. 3 A and B). Secretion of IL-17A from
TH17 cells that were already differentiated from naïve T cells
under TH17-polarizing condition (in vitro differentiated TH17)
and CD4+ CCR6+ cells (in vivo differentiated TH17) were also
inhibited by tRORγt-TMD, suggesting that not only differentia-
tion induction from naïve T cells into TH17 cells but also the
functions of TH17 cells were effectively blocked by tRORγt-TMD
(Fig. S2). However, secretion of IFN-γ, IL-13, or IL-10 production
under TH1-, TH2-, or Treg-polarizing condition was not affected by
tRORγt-TMD (Fig. 3 C–E). When Treg cells were purified and
stimulated with anti-CD3 and anti-CD28 mAb under TH17-polar-
izing condition in the presence of tRORγt-TMD, functional con-
version of Treg cells into TH17 cells was also prevented (Fig. 3F)
(20). These results confirm the inhibitory function and specificity of
tRORγt-TMD on TH17 differentiation and its functions. In agree-
ment with these results, microarray analysis of TH17 cells treated
with tRORγt-TMD also demonstrated that TH17-specific mole-
cules, including IL-21, CCL-2, CCL-20, IL-12Rβ1, and TLR-4, were
down-regulated (Fig. 3G) (21, 22).
tRORγt-TMD Suppresses the Progression of Experimental Autoimmune
Encephalomyelitis in Preventive and Therapeutic Manner. To de-
termine whether tRORγt-TMD can prevent pathogenic pro-
gression of experimental autoimmune encephalomyelitis (EAE),
disease-preventing potential of tRORγt-TMD was examined in
EAE-induced mice in comparison with that of anti-IL17 mAb (23,
24). First, we found that tRORγt-TMD does not have any in vivo
toxicity in mice tissues and did not affect RORγ-related thymocyte
survival (Fig. S3). Then, we confirmed that tRORγt-TMD injected
mice via i.p. route can be delivered into splenic CD4+ T cells (Fig.
S4A). PBS-injected mice started to develop the signs of EAE
around day 9 and reached peak disease manifestation (clinical
score: 3.05 ± 0.23) at day 19. When EAE-induced mice were
treated with tRORγt-TMD every other day from day 1, no EAE-
associated symptoms was observed until day 14. After day 14, some
mice developed mild EAE (clinical score: 0.55 ± 0.27), but they
quickly subsided (Fig. 4A). Anti-IL17 mAb treatment every other
day showed the disease-preventing efficacy similar to that of
tRORγt-TMD (clinical score: 0.5 ± 0.25). To examine the thera-
peutic potential of tRORγt-TMD, EAE-induced mice with a clini-
cal score above 2 were treated with tRORγt-TMD or anti-IL17
mAb from day 16. The tRORγt-TMD and anti-IL17 mAb treat-
ment quickly and markedly suppressed EAE progression (Fig. 4B).
Therefore, specific inhibition of RORγt function in TH17 cells by
tRORγt-TMD has preventive and therapeutic potential for EAE.
To confirm whether the tRORγt-TMD–mediated inhibition of
TH17 differentiation is responsible for its therapeutic effective-
ness on EAE, the level of TH17 cells in the spleen were examined
on day 8 and those in spinal cord on day 5, 8, 11, 16, and 21 after
immunization, respectively. The level of TH17 cells (CD4
+ IL-17A+)
and TH1 cells (CD4
+ IFN-γ+) were significantly reduced in the
spleen/lymph node/spinal cord/brain, and thereby, the number of
both populations in the spinal cord were low in tRORγt-TMD–
treated mice. In anti-IL17 mAb-treated mice, the level of TH17 and
TH1 cells in the spleen/lymph node was comparable to that in PBS-
injected EAE mice, but a low level of TH17 cells was detected
in the spinal cord/brain probably due to the blockage of IL-17A–
dependent infiltration (Fig. 4C and Fig. S5). Therefore, the absolute
number of CD4+ IL-17+ T cells in spinal cord was also decreased
(Fig. 4D). These results were in contrast to the finding that tRORγt-
TMD did not affect IFN-γ secretion under TH1-polarizing condi-
tion (Fig. 3C). Therefore, it is hypothesized that TH17 cells play an
important role in the initial stages of EAE onset and progression,
and generation of encephalogenic TH1 cells depend on the in vivo
inflammatory microenvironment created by the TH17 cells.
To assess the degree of demyelination and inflammation of the
spinal cord and brain of EAE-induced mice treated with tRORγt-
TMD, a histopathological evaluation of the CNS was performed.
In the PBS-injected EAE mice, profound EAE lesions were
detected in the spinal cord accompanying T-cell infitration, de-
myelination, and inflammation. In contrast, in the tRORγt-TMD–
treated mice, all of these symptoms associated with EAE were
significantly diminished in the spinal cord and brain (Fig. 4 E and
F, and Fig. S6). To test effective delivery of tRORγt-TMD into the
spinal cord in vivo and, thereby, suppressed EAE symptoms in
EAE-induced mice, the presence of tRORγt-TMD in the spinal
cord was examined by immunohistochemical staining. Indeed,
significant levels of tRORγt-TMD were detected in the spinal
cord-infiltrating CD4+ T cells prepared at day 21 (Fig. S4B).
tTbet-TMD, Interatomic Inhibitor of Tbet, Suppresses TH1-Mediated
Autoimmunity. To confirm whether this strategy can be applied
to TH1-specific transcription factor, Tbet, tTbet-TMD containing
Hph-1-PTD and TMD of Tbet was generated and intranuclear
delivery of tTbet-TMD was as effecient as that of tRORγt-TMD
Fig. 2. Specific inhibition of IL-17A secretion from TcR-stimulated spleno-
cytes by tRORγt-TMD. (A–C) tRORγt-TMD did not affect the induced ex-
pression of CD69 (A) and FasL (B) on mouse splenocytes, and IL-2 secretion
(C) from the splenocytes activated with plate-bound anti-CD3 and soluble
anti-CD28 antibodies. The cells were stained with anti-CD69 or anti-FasL
mAb and analyzed by FACS, and the level of IL-2 in the culture media was
analyzed by ELISA. (D–F) tRORγt-TMD did not affect cytokine production
from either TH1 (IFN-γ) (D) or TH2 (IL-4) (E) cells. (F) Dose-dependent in-
hibition of IL-17A production from TcR-stimulated splenocytes by tRORγt-
TMD. The levels of IFN-γ, IL-4, or IL-17A in the culture media were analyzed
by ELISA. Data are representative of at least three independent experiments.
Error bars denote SEM. **P < 0.01.





















(Fig. 5A). tTbet-TMD can specifically inhibit the transcription
activity of Tbet binding to the promoter of IFN-γ and block the
differentiation of naïve T cells into TH1 cells without affecting the
differentiation of other T-cell subsets (Fig. 5 B and C). However,
tTbet-TMD (R164A), which cannot bind to the IFN-γ promoter,
failed to attenuate the luciferase activity (25). Additionally, the
clinical severity of arthritis was significantly mitigated by tTbet-
TMD, and its therapeutic efficacy was comparable to that of i.p.-
injected methotrexate (MTX) (Fig. 5 D and E and Fig. S7).
Discussion
RORγt is a major transcription factor that is essential for TH17 cell
differentiation. Thus, it plays critical roles in orchestrating a TH17
cell-mediated inflammatory microenvironment including IL-17
secretion, which often leads to autoimmunity such as rheumatoid
arthritis (RA) and multiple sclerosis (MS). Thereby, it have been well
recognized that inhibition of TH17 cell differentiation and functions
would be an important therapy for such autoimmune diseases. Bio-
logics (ixekizumab, brodalumab, and secukinumab) that inhibit IL-17
functions have been developed, but clinical trials in various autoim-
mune diseases have been reported to be partially successful. It is due
to their ineffective biological activity in some autoimmune diseases
models and their adverse effects in a certain subset of patients. These
results suggested that functional inhibition of RORγt would be more
critical to modulate TH17-mediated autoimmunity rather than tar-
geting individual TH17-specific cytokines and surface molecules.
Sequence analysis revealed that RORγt has transcription
modulation domain (1–99) on N terminus, comprising isotype-
specific domain and DNA-binding domain (DBD), which binds to
the major groove of specific DNA helices (AGGTCA) upstream
of the transcription initiation sites. Ligand-binding domain on C
terminus, linked by the hinge region, contains 12 helices and is
responsible for not only ligand binding but also nuclear localiza-
tion and dimerization (26).
In this study, we developed a novel therapeutic strategy to
suppress the functions of endogenous RORγt in interactomic
and competitive manner by intranuclear delivery of TMD of
RORγt in vitro and in vivo. tRORγt-TMD is a fusion protein be-
tween TMD of RORγt and a human origin Hph-1-PTD that can be
delivered into the nucleus effectively in dose- and time-dependent
manner. tRORγt-TMD, not tRORγt-TMD without DNA-binding
capacity [tRORγt-TMD (RR-AG)], significantly inhibited IL-17A
promoter activity mainly through the competition with endoge-
nous tRORγt for promoter binding. Importantly, tRORγt-TMD
did not affect the APOA5 promoter activity induced by RORα1,
suggesting that transcriptional inhibition of tRORγt-TMD is
highly isotype-specific. tRORγt-TMD suppressed the secretion of
IL-17 from the splenocytes, but neither secretion of TH1- and
TH2-specific cytokines from the splenocytes nor the molecules
induced by TcR stimulation on their surface were affected by
tRORγt-TMD. Consistent with these results, tRORγt-TMD can
prevent TH17 differentiation, but not TH1, TH2, and Treg differ-
entiation even at a level of picomolars. The gene known to be
induced by RORγt such as IL-17A/F, IL-21, CCL-2, CCL-20,
IL-12Rβ1, and TLR-4 were significantly suppressed by tRORγt-
TMD, which was confirmed by microarray analysis.
T cells are known to be crucial for inducing EAE, animal
model of MS, where the inflammatory lesions are characterized
by massive infiltration of inflammatory cells, inducing T cells, B
cells, and macrophages (27, 28). Previously, it has been agreed in
the field that only TH1 plays a critical role in neurologic in-
flammatory disease, but recent reports have emphasized the
pathogenic role of TH17 cells and T cells secreting IL-17/IFN-γ
together rather than that of TH1 (29). Therapeutic potential of
tRORγt-TMD was clearly demonstrated in EAE in a preventive
and therapeutic manner. tRORγt-TMD effectively inhibited
TH17 cell differentiation in the spleen. Thereby, the number of
CD4+ T cells and many inflammatory cells was greatly reduced in
Fig. 3. Differentiation of mouse primary naïve CD4+CD25−CD62Lhigh T cells into TH17 cells was specifically inhibited by tRORγt-TMD. (A–E) The mouse
primary naïve CD4+CD25−CD62Lhigh T cells were incubated with 100 pM or 100 nM of RORγt-TMD, tRORγt-TMD, or tRORγt-LBD for 1 h, and then cells were
stimulated with plate-bound anti-CD3 and soluble anti-CD28 antibodies for 72 h under TH17- (A and B), TH1- (C), TH2- (D), or Treg-polarizing conditions (E). (F)
Treg cells were purified and then treated with tRORγt-TMD or RORγt-TMD under TH17-polarizing condition. The levels of IL-17A, IL-17F, IFN-γ, IL-13, or IL-10 in
the culture media were analyzed by ELISA. (G) Microarray analysis of genes expressed in mouse primary naïve CD4+CD25−CD62Lhigh T cells untreated (TH17) or
treated (tRORγt-TMD I, II) with 100 pM of tRORγt-TMD under TH17-polaring condition. Data are representative of at least three (A–F) independent
experiments. Error bars denote SEM. ***P < 0.001.
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the spinal cord, and the neuronal demyelination was significantly
decreased. As expected, anti-IL17 mAb did not inhibit TH17 cell
differentiation in the spleen, but prevented the migration of TH17
cells into the spinal cord. Interestingly, tRORγt-TMD also blocked
the generation of IFN-γ–secreting CD4+ T cells in the spleen (Fig.
4C). These results may indicate that TH17 cells play an important
role in forming the inflammatory microenvionment including IL-17
secretion at the early stage of EAE, and such inflammatory
condition may involve the generation of a subpopulation of TH17
cells secreting IFN-γ, which has been reported to be pathogenic in
Fig. 4. Preventive and therapeutic potential of tRORγt-TMD in the amelioration of EAE through inhibition of TH17 differentiation and function. (A and B)
Clinical assessment of EAE mice injected with PBS (EAE), tRORγt-TMD (2 mg/kg), or anti-IL17 mAb (2 mg/kg) every other day from day 1 (preventive) (A) or day
16 (therapeutic) (B) after EAE induction. The black arrows indicate the point of the first injection of tRORγt-TMD, and the red arrows indicate the analyzed
day (days 5, 8, 11, 16, and 21). The (-) control is normal mice. (C and D) Splenocytes and mononuclear cells from spinal cord were reactivated with PMA/
ionomycin for 4 h, and then stained for anti-CD4 and intracellular-stained with anti–IL-17A/IFN-γ mAb followed by FACS analysis. Percentages of CD4+ IL-17+/
IFN-γ+ T cells in spleen (C) and absolute number of CD4+ IL-17+ T cells in spinal cord (D) were measured. (E) Inhibition of CD4+ T-cell infiltration into the spinal
cord by tRORγt-TMD during the amelioration of EAE. Mononuclear cells from spinal cord were prepared at different time point. The cells were then stained
for CD4 and analyzed by FACS. The total numbers of CD4+ T-cell in spinal cord were measured. (F) Spinal cord sections obtained from each mouse at day 21
after EAE induction were analyzed for the extent of demyelination and inflammation. Data are representative of more than three experiments with 10 to 40
mice per group (A and B) or one experiment with at least three to five mice per group (C–F). Error bars denote SEM. *P < 0.05, **P < 0.01.
Fig. 5. Preventive potential of tTbet-TMD in the alleviation of CIA. (A) Structure of tTbet-TMD. (B) Competitive inhibition of Tbet-dependent tran-
scriptional activity by tTbet-TMD was analyzed in HEK293 cells cotransfected with the vectors expressing wild-type Tbet and luciferase driven by IFN-γ
promoter. (C ) The mouse primary naïve CD4+CD25−CD62Lhigh T cells were incubated with 1 or 4 μM of tTbet-TMD for 1 h, and then cells were stimulated
with plate-bound anti-CD3 and soluble anti-CD28 antibodies for 48 h under TH1-polarizing conditions. The cells were stained for CD4 and IFN-γ, and then
analyzed by FACS. (D and E ) i.p. injection of MTX (35 mg/kg) and tTbet-TMD (2.5 mg/kg) were performed every other day for 4–8 wk from day 1 after
primary immunization. (D) Inflammatory condition of the paws was observed before mice were killed. (E ) Microscopic analysis of arthritis was assessed by
paw thickness. Data are representative of at least three (B and C ) independent experiments or eight mice per group (D and E ). Error bars denote SEM.
*P < 0.05, ***P < 0.001.





















EAE induction. The expression of GM-CSF, which is the en-
cephalitogenic cytokine produced by TH17 cells, was also inhibited
by tRORγt-TMD (Fig. S8) (30). Transduction capability and the
stable presence of tRORγt-TMD in the spinal cords are syner-
gistically important to suppress the functions of TH17 cells. All of
these therapeutic elements may account for the slightly better
therapeutic efficacy of tRORγt-TMD than that of anti-IL17 mAb
not only in EAE but also in colitis animal model (Fig. S9).
Two previous studies showed that two small molecules tar-
geting the ligand-binding domain of RORγt alleviated autoim-
mune diseases by inhibiting RORγt transcriptional activity (31).
Recently, three small molecules were shown to inhibit the
RORγt-dependent transcriptional network to varying extents and
by divergent mechanisms. One small molecule inhibited RORγt
binding to its target DNA, whereas the other two affected
RORγt-mediated transcription predominantly without removing
DNA binding (14, 32). However, to our surprise, our results
showed that tRORγt-TMD, being as a therapeutic protein, was
much more effective and specific than these small molecules
in modulation of TH17-mediated autoimmunity. tRORγt-TMD
showed a great therapeutic potential in EAE animal model with
less concentration and less treatment frequency compared with
these compounds (33).
Taking these results together, we demonstrated that intera-
comic modulation of RORγt functions is a novel therapeutic
strategy in a variety of diseases with TH17-mediated inflammatory
etiology. Functional inhibition of tRORγt-TMD on human TH17
cells function was also confirmed with human PBMCs (Fig. S10).
IL-17–secreting γδ-T cells were found at high frequencies in the
CNS of mice with EAE and are important for mediating autoim-
mune pathology (34). Inhibition of RORγt in γδ-T cells by
tRORγt-TMD may offer additive effects to its therapeutic activity
because γδ-T-cell–derived IL-17 is one of the earliest sources of the
cytokine after infection (35).
Therapeutic proof of concept of tTF-TMD was confirmed
with Tbet, master TF for TH1 cell differentiation and functions.
Consistent with the results by tRORγt-TMD, tTbet-TMD
inhibited the transcriptional activity of endogenous Tbet and
prevented the differentiation of naïve T cells into TH1 cells, not
into other T-cell subsets. Therapeutic efficacy of tTbet-TMD was
comparable to that of MTX in collagen-induced arthritis (CIA)-
induced animal model of RA.
In conclusion, tRORγt-TMD and tTbet-TMD can be novel
and highly specific therapeutics for the treatment of TH17 and
TH1-mediated inflammatory diseases, and further allows us to
unravel new function of RORγt and Tbet in other immune cells
or in animals without genetic alteration. Moreover, local delivery
of tTF-TMD through the skin barrier has been demonstrated
(36, 37). It is also notable that skin-penetrating capability of
tRORγt-TMD and tTbet-TMD enables its therapeutic potency
to be confined to local lesion area without systemic toxicity in
a case of RA or in many skin autoimmune diseases. This novel
strategy can be easily applicable to development of a novel
therapeutics for the treatment of various diseases, where a spe-
cific transcription factor has a key role in pathogenesis.
Materials and Methods
The RORγt-DBD (RORγt-TMD) and RORγt-LBD that encode amino acids 1–99
and 293–495, respectively, of the wild-type RORγt (1–495) were amplified
from the RORγt plasmid (from D. R. Littman, The Kimmel Center for Biology
and Medicine of the Skirball Institute, New York University School of Med-
icine, New York) by PCR. The tTbet-TMD that encode amino acids 120–336
of the wild-type Tbet were amplified from the Tbet plasmid (from L. H.
Glimcher, Weill Cornell Medical College, New York) by PCR. Animal experi-
mental procedures were approved by Yonsei Laboratory Animal Research
Center (YLARC)-Institutional Animal Care and Use Committee guidelines
(YLARC2010-0035). For details, see SI Materials and Methods.
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